
Caribou is halting vispa-cel and CB-011, allogeneic CAR-T therapies that showed up to 92% response rates, citing a difficult financing environment.
This quiz measures your comprehension of one of our recent feature articles.
A. To streamline the regulatory approval process by prioritizing formulations with the longest shelf life.






